HAPLN1 (Hyaluronan and Proteoglycan Link Protein 1), also known as CRTL1. is a key component of the extracellular matrix (ECM) that stabilizes interactions between hyaluronan and proteoglycans, particularly aggrecan. This glycoprotein plays a critical role in maintaining ECM integrity, which is essential for tissue structure, hydration, and resilience in cartilage, brain, and other connective tissues. HAPLN1 contains immunoglobulin-like and link domains, enabling it to bridge hyaluronan and proteoglycans, thereby supporting ECM organization and biomechanical function.
Antibodies targeting HAPLN1 are valuable tools in studying its expression, localization, and role in physiological and pathological processes. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate HAPLN1's involvement in diseases such as osteoarthritis, intervertebral disc degeneration, and cancer. For example, reduced HAPLN1 levels in cartilage have been linked to ECM degradation in osteoarthritis, while its overexpression in certain tumors may correlate with malignancy or metastasis.
Research also explores HAPLN1's potential as a biomarker or therapeutic target. Antibodies enable mechanistic studies, such as analyzing how HAPLN1 modulates signaling pathways (e.g., TGF-β) or influences cell adhesion and migration. Commercial HAPLN1 antibodies are typically validated for specificity across species, including human and mouse, supporting translational research in regenerative medicine and drug development. Ongoing studies aim to clarify its dual roles in tissue homeostasis and disease progression, highlighting its biomedical relevance.